放疗联合免疫检查点抑制剂在胶质母细胞瘤治疗中的研究进展

Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors in Treatment of Glioblastoma

胶质瘤是颅内最常见的原发性肿瘤,大部分患者表现为胶质母细胞瘤,发病率及致死率极高。尽管胶质母细胞瘤患者经过手术切除联合放、化疗的标准化治疗,但预后仍然很差。近年来,免疫治疗在多种实体肿瘤治疗中取得了突破性进展,但现有数据显示免疫治疗对提高胶质母细胞瘤患者生存期的效果不佳。然而研究表明,免疫治疗可以与放疗产生协同效应,放疗可以增加抗原呈递,并促进促炎性肿瘤微环境的形成,为免疫治疗提供更多相关靶点。本文旨在讨论放疗对肿瘤免疫微环境的影响,以及放疗联合免疫检查点抑制剂在胶质母细胞瘤治疗中的作用。

Glioma is the most common primary intracranial tumor,and most patients present as glioblastoma,with high morbidity and mortality.The prognosis of patients with glioblastoma remains poor after surgical resection combined with standardized treatment of radiotherapy and chemotherapy.In recent years,although the breakthrough of immunotherapy have been achieved in the treatment of a variety of solid tumors,the existing data show that immunotherapy is not effective in improving the survival of patients with glioblastoma.However,studies have shown that immunotherapy can have a synergistic effect with radiotherapy which can increase antigen presentation and promote the formation of pro-inflammatory tumor microenvironment,providing more relevant targets for immunotherapy.The purpose of this paper is to discuss the effect of radiotherapy on tumor immune microenvironment and the role of radiotherapy combined with immune checkpoint inhibitors in the treatment of glioblastoma.